Welcome to the website of Lipopharma, a pioneering clinical-stage biopharmaceutical company that focuses on the discovery, design and clinical development of a new generation of medicines that act through the innovative therapeutic strategy known as “Membrane-Lipid Therapy” (MLT).
Lipopharma arose in 2006 as an academic spin-off of the cellular and molecular biomedicine research group at the University of the Balearic Islands (UIB) in Mallorca, Spain.
Palma de Mallorca, August 1st 2016. – Lipopharma announces the closure of patient recruitment in its first clinical study with Minerval (MIN-001-1203), a Phase I/IIa open label, non-randomized, safety, pharmacokinetics, pharmacodynamics and preliminary efficacy study of Minerval (2OHOA) in adult patients with advanced solid tumors including malignant glioma. Five centres have participated in the study, three in Spain and two in the UK.
54 patients with advanced solid tumours have participated in the Phase I/IIa clinical study with Minerval, half of them with malignant glioma. Results show an excellent safety profile, with no drug-related relevant toxicity effects associated with the investigational product reported, even at doses well above the expected therapeutic range. Very encouraging clinical activity has been observed in nine patients with refractory advanced solid tumours, six of them with malignant glioma.
Palma de Mallorca, April 19th, 2016. – Lipopharma, a pioneering clinical stage biopharmaceutical company developing a new generation of bio-active lipids based on the groundbreaking MLT platform, announced that today the main results of the dose-escalation (DE) part of MIN-001-1203 clinical study with Minerval in patients with advanced solid tumours, including malignant glioma, were presented at the 2016 AACR meeting in New Orleans, LA, by Dr. J. Lopez, Principal Investigator at Royal Marsden Hospital, London, in this study.